134 related articles for article (PubMed ID: 15515769)
1. [Effects of hypericin on traumatic proliferative vitreoretinopathy in rabbits].
Gao Q; Hui Y; Wang Y
Yan Ke Xue Bao; 2002 Dec; 18(4):240-5. PubMed ID: 15515769
[TBL] [Abstract][Full Text] [Related]
2. The antidepressant hypericin inhibits progression of experimental proliferative vitreoretinopathy.
Tahara YR; Sakamoto TR; Oshima YR; Ishibashi TR; Inomata HR; Murata TR; Hinton DR; Ryan SJ
Curr Eye Res; 1999 Oct; 19(4):323-9. PubMed ID: 10520228
[TBL] [Abstract][Full Text] [Related]
3. [Experimental study of vitreoretinal proliferation inhibition by the use of hypericin].
Machado RA; Casella AM; Malaguido MR; Oguido AP
Arq Bras Oftalmol; 2009; 72(5):650-4. PubMed ID: 20027403
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of experimental proliferative vitreoretinopathy with protein kinase C inhibitor (chelerythrine chloride) and melatonin.
Er H; Turkoz Y; Mizrak B; Parlakpinar H
Ophthalmologica; 2006; 220(1):17-22. PubMed ID: 16374044
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of experimental proliferative vitreoretinopathy in rabbits by suramin.
de Souza OF; Sakamoto T; Kimura H; Koda RP; Gabrielian K; Spee C; Ryan SJ
Ophthalmologica; 1995; 209(4):212-6. PubMed ID: 8545096
[TBL] [Abstract][Full Text] [Related]
6. Gene transfer of soluble TGF-beta type II receptor inhibits experimental proliferative vitreoretinopathy.
Oshima Y; Sakamoto T; Hisatomi T; Tsutsumi C; Ueno H; Ishibashi T
Gene Ther; 2002 Sep; 9(18):1214-20. PubMed ID: 12215888
[TBL] [Abstract][Full Text] [Related]
7. An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy.
Cardillo JA; Farah ME; Mitre J; Morales PH; Costa RA; Melo LA; Kuppermann B; Jorge R; Ashton P
Br J Ophthalmol; 2004 Sep; 88(9):1201-5. PubMed ID: 15317716
[TBL] [Abstract][Full Text] [Related]
8. The Effects of Ozurdex® (Dexamethasone Intravitreal Implant) on Experimental Proliferative Vitreoretinopathy.
Kuo HK; Chen YH; Wu PC; Kuo YH
Ophthalmologica; 2015; 233(3-4):198-203. PubMed ID: 25721986
[TBL] [Abstract][Full Text] [Related]
9. Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy.
Nakagawa M; Refojo MF; Marin JF; Doi M; Tolentino FI
Invest Ophthalmol Vis Sci; 1995 Nov; 36(12):2388-95. PubMed ID: 7591628
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative effect of mitomycin C on experimental proliferative vitreoretinopathy in rabbits.
Yu HG; Chung H
Korean J Ophthalmol; 1997 Dec; 11(2):98-105. PubMed ID: 9510652
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy.
Shinohara K; Tanaka M; Sakuma T; Kobayashi Y
Ophthalmic Surg Lasers Imaging; 2003; 34(4):299-305. PubMed ID: 12875458
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of experimental proliferative vitreoretinopathy by retroviral vector-mediated transfer of suicide gene. Can proliferative vitreoretinopathy be a target of gene therapy?
Sakamoto T; Kimura H; Scuric Z; Spee C; Gordon EM; Hinton DR; Anderson WF; Ryan SJ
Ophthalmology; 1995 Oct; 102(10):1417-24. PubMed ID: 9097787
[TBL] [Abstract][Full Text] [Related]
13. [Experimental morphological study of posttraumatic proliferative vitreoretinopathy prevention by cell adhesion peptide Arg-Gly-Asp-Ser].
Khoroshilova-Maslova IP; Babizhaev MA; Kiseleva OA; Ilatovskaia LV
Vestn Oftalmol; 1997; 113(4):27-31. PubMed ID: 9381638
[TBL] [Abstract][Full Text] [Related]
14. Use of caffeic acid phenethyl ester and cortisone may prevent proliferative vitreoretinopathy.
Turkoz Y; Er H; Borazan M; Yilmaz H; Mizrak B; Parlakpinar H; Cigremis Y
Mediators Inflamm; 2004 Apr; 13(2):127-30. PubMed ID: 15203555
[TBL] [Abstract][Full Text] [Related]
15. A new model of proliferative vitreoretinopathy.
Frenzel EM; Neely KA; Walsh AW; Cameron JD; Gregerson DS
Invest Ophthalmol Vis Sci; 1998 Oct; 39(11):2157-64. PubMed ID: 9761295
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotide targeting c-fos mRNA limits retinal pigment epithelial cell proliferation: a key step in the progression of proliferative vitreoretinopathy.
Zhang L; Li X; Zhao M; He P; Yu W; Dong J; Liu G; Li C; Shi X
Exp Eye Res; 2006 Dec; 83(6):1405-11. PubMed ID: 16973160
[TBL] [Abstract][Full Text] [Related]
17. The impact of tacrolimus on growth factors in experimental proliferative vitreoretinopathy.
Turgut B; Uyar F; Ustundag B; Celiker U; Akpolat N; Demir T
Retina; 2012 Feb; 32(2):232-41. PubMed ID: 21934553
[TBL] [Abstract][Full Text] [Related]
18. Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy.
Khanum BNMK; Guha R; Sur VP; Nandi S; Basak SK; Konar A; Hazra S
Eye (Lond); 2017 Sep; 31(9):1317-1328. PubMed ID: 28304388
[TBL] [Abstract][Full Text] [Related]
19. The effect of tranilast on experimental proliferative vitreoretinopathy.
Ito S; Sakamoto T; Tahara Y; Goto Y; Akazawa K; Ishibashi T; Inomata H
Graefes Arch Clin Exp Ophthalmol; 1999 Aug; 237(8):691-6. PubMed ID: 10459620
[TBL] [Abstract][Full Text] [Related]
20. Effects of topoisomerase II inhibitors on retinal pigment epithelium and experimental proliferative vitreoretinopathy.
Kuo HK; Wu PC; Yang PM; Chen YH; Wu YC; Hu DN
J Ocul Pharmacol Ther; 2007 Feb; 23(1):14-20. PubMed ID: 17341145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
